Celgene Corp. has identified substituted imidazopyrazine compounds characterized as interleukin-1 receptor-associated kinase 3 (IRAK-3; IRAK-M) ligands and thus reported to be useful for the treatment of cancer, autoimmune diseases and inflammatory disorders.
Celgene Corp. has described heterocyclic protein-arginine deiminase type-4 (PADI4) inhibitors reported to be useful for the treatment of aging, autoimmune diseases, pain, asthma, inflammatory bowel diseases, AIDS, cancer and Alzheimer's disease, among others.
Taking aim at big pharma’s current penchant for acquisition over in-house innovation, Sen. Elizabeth Warren (D-Mass.) is asking the Federal Trade Commission (FTC) to consider the impact a biopharma merger, whether it’s proposed or a done deal, may have on future innovation.
Celgene Corp. has disclosed sphingosine 1-phosphate receptor 5 (S1PR5; EDG8) modulators reported to be useful for the treatment of Alzheimer's disease and multiple sclerosis.
The U.S. FDA hit a Phoenix-based Abraxis Biosciences LLC facility with a warning letter citing out-of-control aseptic manufacturing processes for Abraxane (paclitaxel), a key chemotherapy drug. The letter, posted Nov. 8, noted that multiple media fill failures occurred last year during simulated aseptic processing operations on the Abraxane filling line.
Beigene Ltd., which in 2019 parlayed exclusive rights to distribute and promote Abraxane (paclitaxel) in China into more than $111 million in revenue, is contesting Celgene parent Bristol Myers Squibb Co.’s cancellation of the deal in arbitration proceedings at the International Chamber of Commerce.
Beigene Ltd., which in 2019 parlayed exclusive rights to distribute and promote Abraxane (paclitaxel) in China into more than $111 million in revenue, is contesting Celgene parent Bristol Myers Squibb Co.’s cancellation of the deal in arbitration proceedings at the International Chamber of Commerce.
Attributing recent reductions in certain U.S. prescription drug prices to intense congressional scrutiny rather than a biopharma industry commitment to affordability, Rep. John Sarbanes (D-Md.) said Congress must put more guardrails in place and restructure how the industry does business.
Rather than the in-your-face, blame-and-shame show that was expected, the Sept. 30 drug pricing hearing before the U.S. House Oversight Committee was more a reminder of the policy differences between Democrats and Republicans on how best to make prescription drugs more affordable.